GlassScriptPhysician profile
Dennis S Wang
NPI 1063588945
$4,738.79
in general payments reported to CMS, 2019-2025
12 companies · $789 in 2025
The $789 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.05 · 2021: $2,714 · 2022: $89.37 · 2023: $101 · 2024: $1,022 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561 · Travel and Lodging: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.00 |
| Travel and Lodging | $351.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,233.44 | 2021-2024 | Da Vinci Surgical System |
| Zimmer Biomet Holdings, INC. | $1,046.24 | 2021-2022 | |
| Ethicon US, LLC | $324.81 | 2020-2025 | Echelon Flex, Harmonic, Enseal |
| Tela Bio, INC. | $243.71 | 2024-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Medtronic, INC. | $185.99 | 2024-2025 | Progrip, Transorb |
| Davol INC. | $184.23 | 2025 | Phasix Mesh |
| Boston Scientific Corporation | $151.50 | 2024 | Axios |
| Phathom Pharmaceuticals, INC. | $111.02 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $95.14 | 2023 | Quviviq |
| Thd America, INC. | $95.14 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $44.77 | 2024 | Andexxa |
| Smith+Nephew, INC. | $22.80 | 2025 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.